JP2021518111A5 - - Google Patents
Info
- Publication number
- JP2021518111A5 JP2021518111A5 JP2020549002A JP2020549002A JP2021518111A5 JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5 JP 2020549002 A JP2020549002 A JP 2020549002A JP 2020549002 A JP2020549002 A JP 2020549002A JP 2021518111 A5 JP2021518111 A5 JP 2021518111A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nucleic acid
- cell
- amino acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114641A JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643139P | 2018-03-14 | 2018-03-14 | |
| US62/643,139 | 2018-03-14 | ||
| PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Division JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518111A JP2021518111A (ja) | 2021-08-02 |
| JP2021518111A5 true JP2021518111A5 (https=) | 2022-03-18 |
| JP7314161B2 JP7314161B2 (ja) | 2023-07-25 |
Family
ID=67907266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549002A Active JP7314161B2 (ja) | 2018-03-14 | 2019-03-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12606603B2 (https=) |
| EP (2) | EP4491718A3 (https=) |
| JP (2) | JP7314161B2 (https=) |
| KR (2) | KR102917671B1 (https=) |
| CN (1) | CN112088165A (https=) |
| AU (2) | AU2019234580B2 (https=) |
| BR (1) | BR112020018534A2 (https=) |
| CA (1) | CA3093791A1 (https=) |
| EA (1) | EA202091984A1 (https=) |
| IL (1) | IL277268A (https=) |
| MX (2) | MX2020009464A (https=) |
| SG (1) | SG11202008926RA (https=) |
| WO (1) | WO2019178085A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765041A4 (en) | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| EP4577575A1 (en) * | 2022-08-25 | 2025-07-02 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| BRPI0819598A2 (pt) | 2007-11-30 | 2017-05-09 | Kalobios Pharmaceuticals Inc | anticorpos para o antígeno pcrv da pseudomonas aeruginosa |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| KR101763499B1 (ko) | 2012-11-07 | 2017-07-31 | 화이자 인코포레이티드 | 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체 |
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| BR112017005631A2 (pt) | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| CN107683289B (zh) | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
| CA2992989A1 (en) | 2015-07-21 | 2017-01-26 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
| WO2017040930A2 (en) * | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| IL287889B2 (en) * | 2016-02-05 | 2024-03-01 | Hope City | Administration of engineered t cells for treatment of cancers in the central nervous system |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| US12304935B2 (en) * | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| AU2017319702B2 (en) | 2016-09-02 | 2024-11-14 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| EP3765041A4 (en) | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
-
2019
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en not_active Ceased
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 US US16/979,475 patent/US12606603B2/en active Active
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt not_active Application Discontinuation
- 2019-03-12 KR KR1020207028968A patent/KR102917671B1/ko active Active
- 2019-03-12 KR KR1020267001996A patent/KR20260021083A/ko active Pending
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 EP EP24214241.2A patent/EP4491718A3/en active Pending
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en not_active Withdrawn
-
2020
- 2020-09-10 MX MX2025010440A patent/MX2025010440A/es unknown
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP7696958B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518108A5 (https=) | ||
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| JP6543626B2 (ja) | 多部分シグナル伝達タンパク質およびその使用 | |
| EP3445847B1 (en) | Immunomodulatory il2r fusion proteins and uses thereof | |
| US20170292118A1 (en) | Method for modulating car-induced immune cells activity | |
| JP7696958B2 (ja) | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 | |
| JP2021518111A5 (https=) | ||
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| WO2023102109A1 (en) | Ex vivo cytokine priming strategies for preparing activated cd26-high immune cells and uses in cancer therapies | |
| JP2023529443A (ja) | 抗ｃｄ１７１キメラ抗原受容体 |